Showing 1 - 8 results of 8 for search 'Ingelise J. Gordon', query time: 0.04s
Refine Results
-
1
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). by Mary E Enama, Julie E Ledgerwood, Laura Novik, Martha C Nason, Ingelise J Gordon, LaSonji Holman, Robert T Bailer, Mario Roederer, Richard A Koup, John R Mascola, Gary J Nabel, Barney S Graham, VRC 011 Study Team
Published 2014-01-01
Article -
2
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. by Barney S Graham, Mary E Enama, Martha C Nason, Ingelise J Gordon, Sheila A Peel, Julie E Ledgerwood, Sarah A Plummer, John R Mascola, Robert T Bailer, Mario Roederer, Richard A Koup, Gary J Nabel, VRC 008 Study Team
Published 2013-01-01
Article -
3
Phase 1 study of pandemic H1 DNA vaccine in healthy adults. by Michelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, Sandra Sitar, Zonghui Hu, Mary E Enama, LaSonji A Holman, Robert T Bailer, Melissa B Pearce, Richard A Koup, John R Mascola, Gary J Nabel, Terrence M Tumpey, Richard M Schwartz, Barney S Graham, Julie E Ledgerwood, VRC 308 Study Team
Published 2015-01-01
Article -
4
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial by Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood
Published 2017-06-01
Article -
5
Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients by Ahmed S. Fahad, Morgan R. Timm, Bharat Madan, Katherine E. Burgomaster, Kimberly A. Dowd, Erica Normandin, Matías F. Gutiérrez-González, Joseph M. Pennington, Matheus Oliveira De Souza, Amy R. Henry, Farida Laboune, Lingshu Wang, David R. Ambrozak, Ingelise J. Gordon, Daniel C. Douek, Julie E. Ledgerwood, Barney S. Graham, Leda R. Castilho, Theodore C. Pierson, John R. Mascola, Brandon J. DeKosky, Brandon J. DeKosky
Published 2021-02-01
Article -
6
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials by Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team
Published 2024-03-01
Article -
7
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase... by Katherine V. Houser, Martin R. Gaudinski, Myra Happe, Sandeep Narpala, Raffaello Verardi, Edward K. Sarfo, Angela R. Corrigan, Richard Wu, Ro Shauna Rothwell, Laura Novik, Cynthia S. Hendel, Ingelise J. Gordon, Nina M. Berkowitz, Cora Trelles Cartagena, Alicia T. Widge, Emily E. Coates, Larisa Strom, Somia Hickman, Michelle Conan-Cibotti, Sandra Vazquez, Olga Trofymenko, Sarah Plummer, Judy Stein, Christopher L. Case, Martha Nason, Andrea Biju, Danealle K. Parchment, Anita Changela, Cheng Cheng, Hongying Duan, Hui Geng, I-Ting Teng, Tongqing Zhou, Sarah O'Connell, Chris Barry, Kevin Carlton, Jason G. Gall, Britta Flach, Nicole A. Doria-Rose, Barney S. Graham, Richard A. Koup, Adrian B. McDermott, John R. Mascola, Peter D. Kwong, Julie E. Ledgerwood
Published 2022-06-01
Article -
8
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine by Joseph P. Casazza, Amelia R. Hofstetter, Pamela J. M. Costner, LaSonji A. Holman, Cynthia S. Hendel, Alicia T. Widge, Richard L. Wu, William R. Whalen, Jennifer Cunningham, Anita Arthur, Xiaolin Wang, Abidemi Ola, Jamie Saunders, Floreliz Mendoza, Laura Novik, Maria C. Burgos Florez, Ana M. Ortega-Villa, Preeti J. Apte, Larisa Strom, Lu Wang, Marjaan Imam, Manjula Basappa, Mursal Naisan, Mike Castro, Jessica F. Trost, Sandeep R. Narpala, Hillary A. Vanderven, Galina V. Yamshchikov, Nina M. Berkowitz, Ingelise J. Gordon, Sarah H. Plummer, Diane L. Wycuff, Sandra Vazquez, Rebecca A. Gillespie, Adrian Creanga, William C. Adams, Kevin Carlton, Jason G. Gall, Adrian B. McDermott, Leonid A. Serebryannyy, Katherine V. Houser, Richard A. Koup, Barney S. Graham, Julie E. Ledgerwood, John R. Mascola, Theodore C. Pierson, Sarah F. Andrews, Masaru Kanekiyo, Lesia K. Dropulic, The VRC 323 study team
Published 2024-09-01
Article